SCHEMBL31358833

SCHEMBL31358833

COC(=O)c1cccc(-c2ccc(C=C3C(=O)c4ccccc4C3=O)o2)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 1/20 0.61
AKT1 P31749 1/20 0.56
PIM1 P11309 2/20 0.55
XPA P23025 1/20 0.54
ALDH1A1 P00352 5/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
KMT2A Q03164 6/20 0.54
POLB P06746 6/20 0.54
MEN1 O00255 5/20 0.54
MAPT P10636 4/20 0.54
KDM4E B2RXH2 3/20 0.54
CTDSP1 Q9GZU7 3/20 0.54
L3MBTL1 Q9Y468 3/20 0.54
PPM1G O15355 1/20 0.54
PTPN1 P18031 1/20 0.54
PTPN7 P35236 1/20 0.54
PTPN5 P54829 1/20 0.54
PTPRO Q16827 1/20 0.54
PTPN22 Q9Y2R2 1/20 0.54
TP53 P04637 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31358750 0.88 POLB (0.69) PIK3CGAKT1PIM1XPAALDH1A1
SCHEMBL31358769 0.87 SIRT2 (0.66) PIK3CGAKT1ALDH1A1SMN1; SMN2KMT2A
SCHEMBL31358664 0.86 PIM1 (0.72) PIK3CGAKT1PIM1ALDH1A1KMT2A
SCHEMBL13072371 0.85 AKT1 (0.60) PIK3CGAKT1PIM1ALDH1A1SMN1; SMN2
SCHEMBL31358823 0.83 PIK3CG (0.58) PIK3CGPIM1XPAALDH1A1SMN1; SMN2
SCHEMBL5145230 0.81 SIRT2 (0.78) PIK3CGPIM1XPASIRT2
SCHEMBL31358764 0.81 AKT1 (0.62) AKT1XPAALDH1A1SMN1; SMN2KMT2A
SCHEMBL31358678 0.80 KDM4E (0.70) AKT1ALDH1A1KMT2APOLBMEN1
SCHEMBL31358723 0.77 MEN1 (0.72) PIK3CGAKT1PIM1ALDH1A1SMN1; SMN2
SCHEMBL31358726 0.77 AKT1 (0.58) AKT1PIM1ALDH1A1SMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026741-A1 INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute 2025-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250026741-A1 INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF PTPN18, PTPN7, PTPN1 PIK3CG 277/4885AKT1 194/4885PIM1 695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.